+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia Pacific Sexually Transmitted Diseases Testing Market By Disease Type, By the Location of Testing Testing, By Country, Opportunity Analysis and Industry Forecast, 2021-2027

  • PDF Icon

    Report

  • 93 Pages
  • January 2022
  • Region: Asia Pacific
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5552892
The Asia Pacific Sexually Transmitted Diseases (STD) Testing Market is expected to witness market growth of 4.5% CAGR during the forecast period (2021-2027).

Some STDs like chlamydial and gonococcal infections in women need etiological identification of STDs that are expensive and advanced laboratory procedures. However, such laboratory tests are not accessible in the developed and developing nations for the patient's assessment, and those that are available are not helpful in determining rapid treatment recommendations. The lack of simple & quick diagnostics for the detection of most STDs, the high cost of existing STD laboratory testing, and the lack of requisite laboratory infrastructure are creating lucrative opportunities for the key market players.

In India, the government has recognized Sexually transmitted diseases (RTIs/STIs) and other reproductive tract infections (RTIs/STIs) as a public health issue, particularly because of their link to HIV infection. RTI/STI prevention, control, and management is a well-known technique for reducing reproductive morbidity among the sexually active population while also regulating the spread of HIV/AIDS in the country. In addition, National AIDS Control Programme run by the Government of India has created more awareness among population along with increasing STD testing in rural areas. Additionally, the introduction of various advanced and effective testing methods in this region is expected to fuel the regional market growth.

The China market dominated the Asia Pacific Sexually Transmitted Diseases (STD) Testing Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $13.00 billion by 2027. The Japan market is poised to grow a CAGR of 3.9% during (2021 - 2027). Additionally, The India market is expected to experience a CAGR of 5.1% during (2021 - 2027).

Based on Disease Type, the market is segmented into Chlamydia, Herpes simplex, Gonorrhea, Syphilis, Human papillomavirus (HPV), and Other Disease. Based on the Location of Testing, the market is segmented into Laboratory Testing and Point of care (POC) Testing. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BioMérieux S.A., Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., DiaSorin Molecular LLC, Danaher Corporation, Bio-Rad Laboratories, Inc., and OraSure Technologies, Inc.

Scope of the Study


Market Segments Covered in the Report:


By Disease Type

  • Chlamydia
  • Herpes simplex
  • Gonorrhea
  • Syphilis 
  • Human papillomavirus (HPV)
  • Other Disease

By Location of Testing

  • Laboratory Testing
  • Point of care (POC) Testing

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Key Market Players


List of Companies Profiled in the Report:

  • BioMérieux S.A.
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Hologic, Inc.
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • DiaSorin Molecular LLC
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • OraSure Technologies, Inc.

Unique Offerings from the Publisher

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Sexually Transmitted Diseases (STD) Testing Market, by Disease Type
1.4.2 Asia Pacific Sexually Transmitted Diseases (STD) Testing Market, by Location of Testing
1.4.3 Asia Pacific Sexually Transmitted Diseases (STD) Testing Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Product Launches and Product Expansions 2019, Oct – 2021, Dec) Leading Players
Chapter 4. Asia Pacific Sexually Transmitted Diseases (STD) Testing Market by Disease Type
4.1 Asia Pacific Chlamydia Market by Country
4.2 Asia Pacific Herpes simplex virus Market by Country
4.3 Asia Pacific Gonorrhea Market by Country
4.4 Asia Pacific Syphilis Market by Country
4.5 Asia Pacific Human papillomavirus (HPV) Market by Country
4.6 Asia Pacific Other Disease Market by Country
Chapter 5. Asia Pacific Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
5.1 Asia Pacific Laboratory Testing Market by Country
5.2 Asia Pacific Point of care (POC) Testing Market by Country
Chapter 6. Asia Pacific Sexually Transmitted Diseases (STD) Testing Market by Country
6.1 China Sexually Transmitted Diseases (STD) Testing Market
6.1.1 China Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.1.2 China Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.2 Japan Sexually Transmitted Diseases (STD) Testing Market
6.2.1 Japan Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.2.2 Japan Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.3 India Sexually Transmitted Diseases (STD) Testing Market
6.3.1 India Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.3.2 India Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.4 South Korea Sexually Transmitted Diseases (STD) Testing Market
6.4.1 South Korea Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.4.2 South Korea Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.5 Singapore Sexually Transmitted Diseases (STD) Testing Market
6.5.1 Singapore Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.5.2 Singapore Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.6 Malaysia Sexually Transmitted Diseases (STD) Testing Market
6.6.1 Malaysia Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.6.2 Malaysia Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.7 Rest of Asia Pacific Sexually Transmitted Diseases (STD) Testing Market
6.7.1 Rest of Asia Pacific Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.7.2 Rest of Asia Pacific Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
Chapter 7. Company Profiles
7.1 BioMérieux S.A.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Research & Development Expenses
7.2 Abbott Laboratories
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments
7.2.5.1 Approvals and Trials
7.3 Becton, Dickinson and Company
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments
7.3.5.1 Product Launches and Product Expansions
7.4 Hologic, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments
7.4.5.1 Approvals and Trials
7.4.5.2 Product Launches and Product Expansions
7.4.5.3 Acquisition and Mergers:
7.5 Thermo Fisher Scientific, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments
7.5.5.1 Partnerships, Collaborations, and Agreements
7.5.6 SWOT Analysis
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments
7.6.5.1 Partnerships, Collaborations, and Agreements
7.6.5.2 Product Launches and Product Expansions
7.7 DiaSorin Molecular LLC
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expenses
7.8 Danaher Corporation
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Bio-Rad laboratories, Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments
7.9.5.1 Acquisition and Mergers:
7.10. OraSure Technologies, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional & Segmental Analysis
7.10.4 Research & Development Expenses
7.10.5 Recent strategies and developments
7.10.5.1 Product Launches and Product Expansions
7.10.5.2 Acquisition and Mergers:

Companies Mentioned

  • BioMérieux S.A.
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Hologic, Inc.
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • DiaSorin Molecular LLC
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • OraSure Technologies, Inc.

Methodology

Loading
LOADING...